α-Synuclein Drug Pipeline in Parkinson’s — PatSnap Eureka
α-Synuclein Drug Pipeline: Aggregation Inhibitors & Immunotherapy in Parkinson's Disease
α-Synuclein misfolding and aggregation into Lewy bodies is a defining pathological feature of Parkinson's disease, affecting over 1 million people in the United States alone. Explore the IP landscape spanning monoclonal antibodies, ASOs, small-molecule inhibitors, and the emerging CAR-Treg frontier.
α-Synuclein: A Multi-Species Target in Parkinson's Disease
α-Synuclein (encoded by the SNCA gene) is the universal target in Parkinson's disease drug discovery. Multiple retrieved filings establish the pathophysiological rationale: α-syn accumulates in Lewy bodies of PD patient brains, mutations in the α-syn gene co-segregate with rare familial parkinsonism, and overexpression in transgenic animals produces disease-relevant pathology. The University of California and Elan Pharmaceuticals were among the first to articulate this framework formally within the patent record.
Critically, retrieved results identify multiple pathological species as distinct intervention points — not a monolithic target. Oligomers are increasingly identified as the primary neurotoxic species, with extracellular oligomers exhibiting neurotoxicity toward brain neuronal plasma membranes. Fibrils form Lewy body inclusions; a prion-like spread hypothesis — whereby pathological α-syn seeds aggregate and propagate to adjacent neurons — is cited across multiple H. Lundbeck A/S filings and underpins the entire passive immunotherapy rationale. Research on these mechanisms is supported by institutions including the National Institutes of Health and published across journals indexed by PubMed/NCBI.
The Scripps Research Institute filings specifically identify Pα-syn* (phospho-Ser129 nonfibrillar mitotoxic species) as a "neurotoxic α-syn species and novel therapeutic target," with evidence of MAPK activation (MKK4, JNK, p38, ERK5), mitochondrial fragmentation, co-localization with phosphorylated tau aggregates, and dendritic spine loss — linking α-syn pathology to tau and synaptic toxicity cascades. This specificity has profound implications for antibody epitope design and small-molecule screening strategies. Learn more about PatSnap's life sciences intelligence solutions for navigating this landscape.
A filing from the Shanghai Institute of Organic Chemistry proposes blocking pathological α-syn interaction with neuronal receptor proteins via C-terminal blockers to inhibit both intraneuronal aggregation and cell-to-cell propagation — a mechanistically distinct approach from fibril-targeting antibodies.
Seven Distinct Approaches Targeting α-Synuclein Pathology
Patent and literature analysis via PatSnap Eureka reveals a rich pipeline spanning immunotherapy, gene silencing, small-molecule chemistry, and novel cell-based strategies.
Passive Immunotherapy — Monoclonal Anti-α-syn Antibodies
The largest cluster of retrieved results. The prion-like spread hypothesis provides the key biological rationale: antibodies neutralizing extracellular α-syn seeds or clearing aggregates could modify disease course. H. Lundbeck A/S leads with at least nine active or pending patent families across AU, CA, EP, HK, IL, IN, NZ, TN, US, and WO. Key antibodies GM37 and GM285 prevent motor phenotype emergence in rat PD models and inhibit α-syn seeding in primary mouse neurons. Biogen reports EC50 = 0.25 nM; >EC90 at 2.1 nM — quantification consistent with clinical development readiness.
H. Lundbeck · Biogen · ABL Bio · MedImmune · UCB · AC ImmuneActive Immunotherapy & CAR-Treg Cell Approaches
The Scripps Research Institute holds multiple patent families covering methods for generating antibodies using Pα-syn* as an immunogen — presenting conformational epitopes not accessible on monomers or fibrils. A landmark 2025 WO filing describes a CAR-Treg approach: monoclonal antibody clone 1A11 recognizes three nitrated tyrosines (3NYαSyn) in the C-terminal sequence of human α-syn. A CAR incorporating 1A11 fused to CD3ζ and CD28 was expressed in Tregs; these CAR-Tregs attenuated neurodegeneration and reduced dopaminergic neuron loss in a preclinical mouse model — the only cell-based immunotherapy approach retrieved in this dataset.
Scripps Research · University of California · CAR-Treg (2025 WO)Antisense Oligonucleotides (ASOs) Targeting SNCA
The University of Pennsylvania holds WO, CA, and AU patent families on FANA (2'-fluoroarabinonucleic acid) antisense oligonucleotides — described as a "seminal discovery" for PD treatment — that decrease α-syn expression in neurons and reduce Lewy body and Lewy neurite pathology. Ionis Pharmaceuticals holds a pending IL filing covering oligomeric compounds for reducing SNCA mRNA and α-syn protein levels across PD, DLB, PDD, PAF, MSA, neuronopathic Gaucher's disease, and Alzheimer's disease. Both programs are NIH-supported, indicating translational intent.
Univ. Pennsylvania (FANA ASOs) · Ionis PharmaceuticalsSmall-Molecule Aggregation Inhibitors
Multiple distinct chemical strategies appear in the dataset. WiSTA Laboratories' diaminophenothiazines are claimed to inhibit or reverse α-syn aggregation with active ES patent protection. Kainos Medicine's aminopyrazole compounds modulate α-syn levels via FAF1 inhibition and LC-3/p62-mediated autophagy, decreasing pSer129-α-syn. AC Immune SA's bicyclic compounds serve dual diagnostic and therapeutic roles — binding α-syn aggregates (Lewy bodies and Lewy neurites) for both imaging and treatment. The University of California's structure-based peptide inhibitors bind α-syn and inhibit amyloidogenic aggregation, cytotoxicity, and spread in PD, DLB, and MSA.
WiSTA · Kainos Medicine · AC Immune · Univ. California · PanaceaRepurposing & Combination Approaches
University Health Network (WO 2023, US 2025 pending) claims methods for treating α-synucleinopathy disorders using rifabutin, nucleoside analog reverse transcriptase inhibitors (lamivudine, emtricitabine, tenofovir disoproxil fumarate, tenofovir alafenamide, abacavir, zidovudine, didanosine, stavudine), and/or losartan — applying antiviral and antihypertensive agents to α-syn-mediated neurodegeneration. H. Lundbeck A/S also explicitly claims combination regimens pairing anti-α-syn mAbs with additional medicaments, suggesting multi-target co-administration as a core commercial strategy.
University Health Network · H. Lundbeck (mAb combinations)Optogenetic Screening in Patient-Derived Neurons
The Johns Hopkins University holds WO and US (pending) filings on an optogenetic α-syn aggregation system developed in PD-hiPSC-derived midbrain dopaminergic (mDA) neurons. Light-activated α-syn fusion proteins enable controlled aggregation in human patient-derived neurons, providing a platform to screen drug candidates in disease-relevant human cells. Retrieved data includes SMILES strings for identified candidates (e.g., cyclothiazide), with neuroprotective effects demonstrated in vitro and in vivo. This platform bridges target biology and compound discovery in a clinically relevant cellular model.
Johns Hopkins University · PD-hiPSC-mDA neurons · cyclothiazidePatent Activity Across Modalities & Key Assignees
Data derived from patent filings analysis via PatSnap Eureka. All values represent filings captured within the retrieved dataset.
Therapeutic Modality Distribution in α-Syn Pipeline
Passive immunotherapy (mAbs) dominates the retrieved patent dataset, followed by small-molecule inhibitors and ASO/RNAi approaches.
Biogen Anti-α-syn Antibody: Dose-Response Parameters
Quantitative pharmacological data from Biogen's IL filing indicates IND-enabling or clinical-stage development readiness, with EC50 = 0.25 nM and >EC90 achieved at 2.1 nM.
Key Organizational Actors in the α-Syn Patent Pipeline
Innovation in this dataset is predominantly patent-driven, reflecting the commercial development phase of the field. Below are the principal assignees and their strategic positioning.
| Assignee | Country | Modality | Jurisdictions | Key Assets / Notes |
|---|---|---|---|---|
| H. Lundbeck A/S | Denmark | Passive mAb | AU, CA, EP, HK, IL, IN, NZ, TN, US, WO (10) | GM37, GM285; prevents motor phenotype in rat model; combination regimens claimed |
| AC Immune SA | Switzerland | Small Molecule + mAb | CA, EP, IN, NZ, SG, US, WO (7) | Bicyclic compounds for dual diagnostic/therapeutic use; theranostic strategy |
| Biogen International Neuroscience GmbH | Switzerland/Germany | Passive mAb | SG, IL (2) | EC50 = 0.25 nM; >EC90 at 2.1 nM; dosage regimen claims for PD, DLB, MSA, PDD |
| ABL Bio Incorporated | South Korea | Passive mAb | JP (3 active patents) | Preferentially recognizes α-syn aggregates over monomers; inhibits intercellular transmission |
| The Scripps Research Institute | USA | Active Immunotherapy | PCT, WO, CA, AU, US, JP | Pα-syn*-based antibody generation; NIH-supported; multiple jurisdictions |
| Univ. of Pennsylvania | USA | ASO | WO, CA, AU (3) | FANA ASOs — "seminal discovery"; NIH-supported; reduces Lewy body pathology |
| Ionis Pharmaceuticals | USA | ASO | IL (pending) | SNCA mRNA-targeting oligomeric compounds; broad synucleinopathy utility |
| Kainos Medicine Inc. | USA/Korea | Small Molecule | IL (multiple active, 2020 & 2023) | Aminopyrazole FAF1 modulators; reduces pSer129-α-syn via autophagy promotion |
Need Freedom-to-Operate Analysis for α-Syn Targets?
PatSnap Eureka's AI maps claim scope across all active jurisdictions in seconds. Explore PatSnap Analytics for IP landscape tools.
Emerging Directions & Strategic Implications
Convergent signals from patent analysis point to six strategic directions shaping the next generation of α-syn therapeutics.
Prion-Like Spread as Dominant mAb Rationale — But Differentiated Epitope Space Emerging
The prion-like spread hypothesis is the dominant mechanistic rationale for antibody approaches in this dataset. However, the Scripps Pα-syn* and the 3NYαSyn CAR-Treg approaches target distinct, conformationally or post-translationally modified species — potentially offering differentiated epitope space for next-generation immunotherapeutics not covered by existing Lundbeck, Biogen, or UCB claims.
Passive Immunotherapy IP Is Deeply Contested Across Overlapping Jurisdictions
H. Lundbeck A/S, Biogen, ABL Bio, MedImmune, UCB, and AC Immune all hold active anti-α-syn antibody patents across overlapping jurisdictions. IP freedom-to-operate analysis is essential for any new entrant. Combination therapy claims by H. Lundbeck represent a potential blocking strategy for co-administration scenarios. PatSnap's Trust Center provides guidance on IP data security.
α-syn / Tau Biology Convergence Points to Combined Targeting Strategies
The Scripps Research Institute filings describe Pα-syn* co-localizing with phosphorylated tau aggregates and inducing GSK3β and MKK4/JNK/p38/ERK5 activation — pointing toward combined α-syn/tau targeting strategies as a potential direction. This mechanistic link also suggests that α-syn therapeutics may need to address broader tauopathy pathways for meaningful disease modification, consistent with Alzforum reporting on dual-target approaches.
Repurposing & Combination Strategies Signal Single-Agent Insufficiency
University Health Network's filings on NRTIs (lamivudine, emtricitabine, tenofovir disoproxil fumarate, tenofovir alafenamide, abacavir, zidovudine, didanosine, stavudine), rifabutin, and losartan — alongside H. Lundbeck's mAb combination claims — signal an acknowledgment that single-agent α-syn targeting may be insufficient. Multi-target approaches addressing neuroinflammation, autophagy, mitochondrial health, and prion-like spread simultaneously may be required for meaningful disease modification.
Development Stage Indicators Across the α-Syn Pipeline
Retrieved results provide limited direct evidence of clinical translation, but several signals are present. The Biogen International Neuroscience GmbH filing reports quantitative antibody dose-response parameters (EC50 = 0.25 nM; >EC90 at 2.1 nM) — a level of pharmacological characterization typically associated with IND-enabling or clinical-stage development. The explicit claim of dosage regimens, including specification of mild vs. moderate PD as treatment subpopulations, further suggests clinical development readiness. ClinicalTrials.gov can be cross-referenced for active synucleinopathy trials.
H. Lundbeck A/S antibodies GM37 and GM285 are described as preventing motor phenotype in a rat PD model and inhibiting α-syn seeding in primary mouse neurons — data typically generated in advance of or during IND-enabling studies. The 2025 CAR-Treg WO filing (Mass, 2025) describes attenuation of dopaminergic neuron loss in a preclinical mouse model, framing the approach as "a promising therapeutic strategy" — language consistent with early preclinical positioning.
Both Chiba University and the University of Pennsylvania reference NIH government grants supporting their research — a common indicator of academic-to-clinical translational intent. The PatSnap customer success stories include life sciences teams using Eureka to track exactly these translational signals at scale. Importantly, no regulatory submissions, IND filings, or clinical trial outcome data were retrieved in this dataset — their absence does not indicate non-existence in the broader landscape.
- Biogen: EC50 = 0.25 nM; >EC90 at 2.1 nM — IND-enabling characterization level
- H. Lundbeck GM37 & GM285: motor phenotype prevention in rat PD model
- CAR-Treg (Mass, 2025 WO): dopaminergic neuron loss attenuation in mouse model
- UPenn FANA ASOs & Chiba University: NIH grant support signals translational intent
- No IND filings or clinical trial outcome data retrieved in this dataset
α-Synuclein Drug Pipeline in Parkinson's Disease — Key Questions Answered
α-Synuclein (encoded by the SNCA gene) is the central therapeutic target in Parkinson's disease. It accumulates in Lewy bodies of PD patient brains, mutations in the α-syn gene co-segregate with rare familial parkinsonism, and overexpression in transgenic animals produces disease-relevant pathology. Multiple pathological species — oligomers, fibrils, phosphorylated Pα-syn*, and C-terminal truncated fragments — are each identified as distinct intervention points.
H. Lundbeck A/S is the single most active assignee in the dataset, with active or pending filings in at least 10 jurisdictions (AU, CA, EP, HK, IL, IN, NZ, TN, US, WO). Other key holders include Biogen International Neuroscience GmbH, ABL Bio Incorporated, MedImmune Limited, UCB Biopharm SRL, and AC Immune SA.
The principal modalities include passive immunotherapy (monoclonal anti-α-syn antibodies), active immunotherapy and antibody generation strategies, antisense oligonucleotides (ASOs) targeting SNCA, small-molecule aggregation inhibitors, drug repurposing and combination approaches, optogenetic screening platforms for inhibitor discovery, and gene silencing via siRNA/RNAi.
A recent WO filing describes monoclonal antibody clone 1A11 that recognizes a C-terminal sequence of human α-syn containing three nitrated tyrosines (3NYαSyn) and does not bind the unmodified sequence. A CAR incorporating the 1A11 antigen-recognizing domain fused to CD3ζ and CD28 intracellular signaling was expressed in Tregs; these CAR-Tregs attenuated neurodegeneration and neuroinflammation and reduced dopaminergic neuron loss in a preclinical mouse model.
The Biogen International Neuroscience GmbH filing reports quantitative antibody dose-response parameters (EC50 = 0.25 nM; >EC90 at 2.1 nM), a level of pharmacological characterization typically associated with IND-enabling or clinical-stage development. H. Lundbeck antibodies GM37 and GM285 prevent motor phenotype in a rat PD model. No regulatory submissions, IND filings, or clinical trial outcome data were retrieved in this dataset.
The Trustees of the University of Pennsylvania hold patent families on FANA (2'-fluoroarabinonucleic acid) antisense oligonucleotides targeting α-syn, which decrease α-syn expression in neurons and reduce Lewy body and Lewy neurite pathology. Ionis Pharmaceuticals, Inc. holds a pending IL filing covering compounds and methods for reducing SNCA mRNA and α-syn protein levels across PD, DLB, PDD, PAF, MSA, and other synucleinopathies.
Still have questions about the α-syn patent landscape? Let PatSnap Eureka answer them for you.
Ask Eureka AI About α-Syn PatentsAccelerate Your α-Synuclein Drug Discovery with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map competitive IP, identify white space, and track emerging modalities in Parkinson's disease and synucleinopathies. Explore PatSnap's API for programmatic access to innovation data.
References
- Agents, uses and methods for the treatment of synucleinopathy — H. Lundbeck A/S, 2018, US [Patent]
- Agents, uses and methods for the treatment of synucleinopathy — H. Lundbeck A/S, 2018, WO [Patent]
- Agents, uses and methods for the treatment of synucleinopathy — H. Lundbeck A/S, 2024, AU [Patent]
- Antibodies binding alpha-synuclein and uses thereof — H. Lundbeck A/S, 2025, CA [Patent]
- Compositions and methods for treating synucleinopathies — Biogen International Neuroscience GmbH, 2019, IL [Patent]
- Compositions and methods for treating synucleinopathies — Biogen International Neuroscience GmbH, 2019, SG [Patent]
- Antibodies to alpha-synuclein and uses thereof — ABL Bio Incorporated, 2023, JP [Patent]
- Antibodies to alpha-synuclein and uses thereof — MedImmune Limited, 2019, JP [Patent]
- Anti-α-synuclein antibody — UCB Biopharm SRL, 2021, JP [Patent]
- Novel molecules for therapy and diagnostics — AC Immune SA, 2022, JP [Patent]
- Methods related to Parkinson's disease and synucleinopathies — The Scripps Research Institute, 2019, WO [Patent]
- Parkinson's disease therapy by developing a Treg-mediated response specific to alpha-synuclein — Mass, Clifford J., 2025, WO [Patent]
- Antisense oligonucleotides for treatment of neurological disorders — The Trustees of the University of Pennsylvania, 2021, WO [Patent]
- Compounds and methods for modulating alpha-synuclein expression — Ionis Pharmaceuticals, Inc., 2025, IL [Patent]
- Inhibitors of protein aggregation — WiSTA Laboratories Ltd., 2018, ES [Patent]
- Modulators of alpha-synuclein — Kainos Medicine Inc., 2023, IL [Patent]
- Structure-based peptide inhibitors of alpha-synuclein aggregation — The Regents of the University of California, 2019, IL [Patent]
- Optogenetic alpha-synuclein aggregation system-based compound screening platform in PD-hiPSC-mDA neurons — The Johns Hopkins University, 2024, WO [Patent]
- National Institutes of Health (NIH) — Parkinson's Disease Research Program
- PubMed/NCBI — α-Synuclein Literature Database
- ClinicalTrials.gov — Synucleinopathy Clinical Trials Registry
- Alzforum — α-Synuclein Research News & Drug Pipeline Tracker
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.